miR-372 and miR-373 enhance the stemness of colorectal cancer cells by repressing differentiation signaling pathways

Lu-Qin Wang, Peng Yu, Bin Li, Yan-Hua Guo, Zi-Rui Liang, Ling-Ling Zheng, Jian-Hua Yang, Hui Xu, Shun Liu, Li-Si Zheng, Hui Zhou and Liang-Hu Qu

Key Laboratory of Gene Engineering of the Ministry of Education, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, China

Keywords
cancer stem cell; colorectal cancer; miR-372/373; NFκB; SPOP; VDR

Correspondence
L.-H. Qu, Key Laboratory of Gene Engineering of the Ministry of Education, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510275, China
Fax: +86 20 84036551
Tel: +86 20 84112399
E-mail: lssqlh@mail.sysu.edu.cn

Lu-Qin Wang and Peng Yu contributed equally to this work.

(Received 19 May 2018, revised 28 July 2018, accepted 10 August 2018, available online 24 September 2018)
doi:10.1002/1878-0261.12376

1. Introduction

MicroRNAs (miRNAs) are a class of small non-coding RNAs of 20–25 nucleotides in length that bind to the 3′ UTR of specific target mRNAs to regulate global gene expression by suppressing protein translation (Bartel, 2004). Previous studies showed that most miRNAs are limited to specific stages in embryonic development (Landgraf et al., 2007; Wienholds et al., 2005) and are often deregulated during tumorigenesis (Calin et al., 2004; Volinia et al., 2006), and also they regulate developmental events throughout embryogenesis (Ivey and Srivastava, 2010) and tumor development in various cancers.
miR-372/373 induced cancer stem cell phenotypes

L.-Q. Wang et al.

2. Materials and methods

2.1. Cell culture and transfection

HCT116 and 293FT cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum. RKO cells were maintained in MEM with 10% fetal bovine serum. Caco-2 cells were maintained in MEM medium with 20% fetal bovine serum. HCT116, RKO and Caco-2 cells were purchased from the Chinese Science Academy (Beijing, China) and 293FT cells were purchased from Invitrogen (Carlsbad, CA, USA). All cells were cultured at 37 °C with 5% CO2.

All cell transfections were performed using Lipofectamine 2000 transfection reagent (Invitrogen) in accordance with the manufacturer’s instruction. RNA (Ribo, Guangzhou, China) transfections were performed at a final concentration of 50 nm.

2.2. Generation of stable cell lines

Establishment of the HCT116 pSNCG-miR-372/373 and RKO pSNCG-miR-372/373 stable cell lines was performed as described previously (Xu et al., 2010). Briefly, lentiviruses were generated by co-transfection 3 µg of transfer vector and 9 µg of packaging mix in 293FT cells. Supernatants were collected 48 h after transfection, filtered through a 0.45 µm membrane and used to infect cells in the presence of polybrene (6 µg·mL−1). Geneticin (1000 µg·mL−1) was used to select positive cells.

Establishment of the Caco-2 TuD-miR-372/373 stable cells was performed using pGreen-Puro lentiviral vector (System Biosciences, Palo Alto, CA, USA). Lentiviruses were generated by co-transfection using 12 µg of transfer vector and 12 µg of packaging mix in 293FT cells. Puromycin (1 µg·mL−1) was used to select positive cells.

2.3. miRNA sequencing

Total RNA was extracted using TRIzol reagent (Invitrogen). The small RNA (sRNA) was isolated by separating 10 µg of total RNA on denaturing polyacrylamide gel electrophoresis and excising the portion of the gel corresponding to 18–30 nucleotides based on oligonucleotide markers. Adapters (5’ and 3’) were ligated to the sRNA population. Modified sRNAs were reverse transcribed and PCR-amplified with adapter-specific primers. The amplified cDNAs were purified by urea-polyacrylamide gel electrophoresis for
sequencing with a genome analyzer (Illumina, Inc., San Diego, CA, USA).

2.4. Flow cytometry assay

Cells were digested by trypsin and $1 \times 10^6$ cells were suspended in 100 µL of PBS for each assay. For CD133 detection, the cell suspension was stained with a CD133 fluorescence-labeled antibody (Miltenyi Biotec, Bergisch Gladbach, Germany) at 4 °C for 10 min. For CD44, CD24 and CD26 detection, the cell suspensions were stained with CD44, CD24 and CD26 fluorescence-labeled antibodies (eBioscience, San Diego, CA, USA), respectively, at 37 °C for 30 min. The negative control included cells incubated with isotype control antibodies for each color. Fluorescence signals were analyzed using fluorescence activated cell sorting (FACS) on a BD FACS Calibur flow cytometer (BD Biosciences, San Jose, CA, USA).

2.5. Sphere formation assay

Cells ($3 \times 10^3$) were seeded in six-well ultra-low attachment surface plates (Corning, New York, NY, USA) and cultured in DMEM/F12 serum-free medium (Gibco, Life Technologies, Scoresby, VIC, Australia) supplemented with B27 (Invitrogen), 20 ng/mL of EGF (Invitrogen) and 20 ng/mL of bFGF (Invitrogen) for 7 days. The spheres were photographed and counted under a Zeiss Axio Observer.Z1 (Carl Zeiss, Oberkochen, Germany) at a magnification of 20×.

2.6. 5-Fluorouracil treatment

HCT116 stable cells were collected and $3 \times 10^4$ cells were seeded in 24-well plates and incubated at 37 °C in a humidified CO₂ incubator. After 24 h, the medium was aspirated and replaced with growth media containing 5, 10, 15, 20 or 25 µM 5-fluorouracil (Sigma-Aldrich, St Louis, MO, USA). After 72 h, the viable cells were collected and seeded in 96-well plates and examined using a Cell Counting Kit-8 (Dojindo, Shanghai, China).

2.7. Migration and invasion assay

For migration and invasion assays, the cells were suspended in 200 µL of medium without fetal bovine serum and were then seeded into the upper chamber of Transwell inserts (8 µm pore size; Corning) with or without a Matrigel (R&D Systems, Minneapolis, MN, USA) coating. The lower chamber of the Transwell was filled with 750 µL of medium supplemented with 10% fetal bovine serum, which functions as a chemoattractant. After 24 h of incubation at 37 °C, cells that migrated or invaded the lower surface of the insert membrane were fixed in methanol and stained with 0.1% crystal violet. The cells that migrated or invaded were photographed under a Zeiss Axio Observer.Z1 (Carl Zeiss) at a magnification of 20×. Numbers of cells were analyzed by IMAGE PRO-PLUS (Media Cybernetics, Inc., Bethesda, MD, USA).

2.8. Animal study

The 4–6-week-old female BALB/c nude mice were purchased from Guangdong Medical Laboratory Animal Center (Guangzhou, China). The experiments were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals (NIH publication No. 80-23, revised 1996) and according to the ethical principles for experiments on animals of Institutional Animal Care and Use Committee of Sun Yat-sen University. For each group, five mice were used. For each mouse, $2 \times 10^6$ HCT116 cells suspended in 200 µL of 1 × PBS were injected subcutaneously into the dorsal flank. Tumor growth was confirmed and recorded by two investigators. The mice were euthanized 20 days after injection. Tumor tissue protein was extracted by TRIzol reagent (Invitrogen).

2.9. Quantitative RT-PCR

Total RNA was extracted by TRIzol reagent (Invitrogen). Quantitative RT-PCR assays were performed using SYBR PrimeScript™ RT-PCR kit (Takara Bio Inc., Otsu, Japan) as described previously (Xu et al., 2010). For reverse transcription reactions, stem loop reverse transcript primers were used for miRNAs and oligo dT mixed with random primers was used for mRNAs. The primers used for real-time PCR are listed in Table S1. The specificities of primer were analyzed both using in silico primer-blast and melting curve detection.

2.10. Western blotting

Protein samples were extracted with TRIzol reagent (Invitrogen) and were dissolved in an amphoteric electrolyte. Western blot assays were performed as described previously (Huang et al., 2012). Nitrocellulose membranes were blocked using 5% Blotting Grade Blocker Non-Fat Dry Milk (Bio-Rad, Hercules, CA, USA) and were then incubated with primary antibodies at 4 °C overnight. For primary antibodies, anti-CD26 was purchased from R&D Systems.
anti-CD44, anti-p65, anti-p-p65, anti-SETD7 anti-VDR and anti-GAPDH were purchased from Cell Signaling Technology (CST, Danvers, MA, USA); and anti-SPOP was purchased from Proteintech (Wuhan, China). The blots were then incubated with horseradish peroxidase-conjugated secondary antibody (CST) at room temperature for 1 h. Bands were analyzed by gel-pro analyzer software (Media Cybernetics).

2.11. Vector construction

For the stable miRNA expressing vector, an approximately 300 bp DNA fragment containing pre-miR-372 or pre-miR-373 was amplified from SW480 genomic DNA and cloned into the pISNCG vector. For miRNA transient overexpression vectors, the 300 bp DNA fragment containing the entire pre-miR-372 or pre-miR-373 sequence was cloned into the pcDNA6.2 vector (K4936-00; Invitrogen). For the stable miR-TuD-expressing vector, the 146 nt TuD stem loop sequence, which could sequester miR-372/373, was synthesized and then cloned into the pGreen-Puro vector (System Bioscience).

For target validation, both strands of the 59 nucleotide 3′ UTR sequence containing the miRNA binding region of each target gene were synthesized, directly annealed and then cloned into the psiCheck2 vector (Promega, Madison, WI, USA).

For gene overexpression vectors, the RNA was reverse transcribed and fragments containing the VDR, SPOP and SETD7 were amplified and cloned into the pcDNA3.1 vector (V790-20; Invitrogen).

Cignal 45-pathway reporter arrays that measure the activity of the 45 pathway were purchased from Qiagen (Hilden, Germany).

Primers for vector construction are listed in Table S2.

2.12. Luciferase reporter assay

For pathway activity assays, 3.5 × 10⁴ HCT116 cells were plated in 48-well plates and transfected with 50 ng of pGL4.11-enhancer reporter vectors and 2.5 ng of pRL-TK Renilla control vector. For target 3′ UTR luciferase assays, HCT116 cells were plated in 48-well plates and transfected with 100 ng of pcDNA6.2-miR-372/miR-373 and 100 ng of psiCheck2 target 3′UTR vector. After 48 h, the luciferase assay was performed using a Dual-Luciferase Reporter Assay System (Promega) on a GloMax 96 Microplate Luminometer (Promega).

2.13. Statistical analysis

The data were presented as the mean ± SEM of three separate experiments, unless otherwise stated. If the data followed Gaussian distributions, a Student’s t-test was conducted. If the data did not follow Gaussian distributions, the Wilcoxon rank-sum test was used. The RNA-sequencing data and the corresponding clinical information were downloaded from TCGA. The clinical correlation was analyzed by the chi-squared test. P < 0.05 was considered statistically significant.

3. Results

3.1. miR-372/373 are upregulated in CRC and involved in CSC properties

To study the expression pattern of miR-372/373 in CRC, we characterized the expression of miR-372/373 in 607 CRC tissue samples and 11 adjacent normal colon tissues available from TCGA. We found that miR-372/373 were not expressed in normal adjacent colon tissues, although they were highly expressed in lots of CRC tissues (Fig. 1A). We further examined the expression of the miR-372/373 in CRC cell lines and found that miR-372/373 were high in CRC cell lines Caco-2 and HCT15 cells; low in CRC cell lines RKO and HCT116; and almost not expressed in normal human colon CCD-18Co cells (Fig. 1B). These data indicate that expression of miR-372/373 could be associated with a characteristic of CRC. To explore the possible involvement of miR-372/373 in CSC properties, we examined the expression of the CSC markers Nanog and CD24 genes in CRC cell lines. As shown in Figs 1B and S1A, the expression patterns of miR-372/373 were significantly correlated with Nanog and CD24 in these cell lines, suggesting that the miR-372/373 are related to CSC features.

To confirm the involvement of miR-372/373 in CSC properties, a lentivirus system stably overexpressing miR-372 and miR-373 or their decoy RNAs in CRC cell lines was established (Fig. 1C). We first overexpressed miR-372/373 in HCT116 cells because these cells express low endogenous miR-372/373. Significant upregulation of miR-372/373 in these stably overexpressed cells was detected and their expression levels in HCT116 overexpressed cells are within the scope of a patient derived Caco-2 cell line (Fig. 1D). We assessed the features of the cell population using FACS analysis. CD44, CD24, CD133 and CD26 were previously identified as CSC surface markers and as indicators of higher tumorigenic capability or with an invasive potential for CRC (King et al., 2012; O’Brien et al., 2007; Pang et al., 2010; 1952 Molecular Oncology 12 (2018) 1949–1964 © 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Yeung et al., 2010). FACS analysis demonstrated that the percentage of CD24+, CD26+ (Fig. 1E), CD44+ and CD133+ (Fig. S2A) cells was significantly increased in miR-372/373-expressing HCT116 cells. RKO cells that also express low endogenous miR-372/373 levels were analyzed. FACS analysis showed that RKO cells stably overexpressing miR-372/373 had increased CSC surface markers (Figs S1B and S2B). By contrast to in HCT116 cells, miR-372/373 are among the most abundant endogenous miRNAs in Caco-2 cells. We therefore established new Caco-2 cells lines stably expressing touch decoy RNAs (Haraguchi et al., 2009) against miRNA-
miR-372/373 induced cancer stem cell phenotypes

L.-Q. Wang et al.

372 and miR-373 (denoted TuD-miR-372/373) to achieve long-term suppression of miR-372/373 activity (Figs 1C and S1B,C). FACS analysis revealed that the competitive inhibition of miR-372/373 reduced the CD24+ and CD26+ cell populations in Caco-2 cells (Fig. 1F). These results indicate that miR-372/373 are positively correlated with the CSC population in various CRC cells.

Moreover, to evaluate the impact of an ectopic miRNA with respect to CRC cells, we analyzed the miRNA profiles by deep sequencing in HCT116 cells overexpressing miR-372/373. In addition to the significant upregulation of miR-372/373, a large amount of miRNA was changed compared to the control. Particularly, a series of stem cell-specific miRNAs, such as miR-302 (Bourguignon et al., 2012; Lin et al., 2011; Subramanyam et al., 2011), miR-130 (Ma et al., 2010; Pfaff et al., 2011) and miR-181 (Ji et al., 2009, 2011; Judson et al., 2013; Wang et al., 2011), were upregulated, and stemness-depressed miRNAs, such as miR-145 (Jia et al., 2012; Ren et al., 2013; Xu et al., 2009), were downregulated, in miR-372/373-expressing cells (Fig. 1G). These results indicated that the overexpression of miR-372/373 enables stem-related miRNAs to change and synergistically promote stem-like properties with respect to HCT116 cells.

3.2. Overexpression of miR-372/373 promoted CSC phenotype of CRC cells in vitro and in vivo

To assess the self-renewal ability, the stable cells were maintained in stem cell culture medium, which allows cells with the capacity of self-renewal to form spheres. As expected, more spheres formed in miR-372- and miR-373-expressing HCT116 cells (Fig. 2A) and competitive inhibition of miR-372/373 reduced the sphere numbers in Caco-2 cells (Fig. 2A). To examine drug resistance, HCT116 cells were treated with different doses of the chemotherapeutic drug 5-fluorouracil for 72 h and cell viability was then determined. As expected, cells with enforced expression of miR-372 and miR-373 were more resistant to the 5-fluorouracil treatment (Fig. 2B). In addition, the competitive inhibition of miR-372/373 did not significantly reverse the effect of drug resistance in Caco-2 cells, indicating that the efficiency of TuD may be not sufficiently high to reverse all of the effect of the overexpression of miRNA-372/373. A Transwell assay was performed to determine the migration and invasion potency of stable cells. Compared to the control group, enforced expression of miR-372/373 enhanced the migration and invasion of HCT116 cells (Fig. 2C) and RKO cells (Fig. S2C). Taken together, these data suggested that miR-372/373 promoted CSC properties of CRC cells.

Having obtained evidence indicating that miR-372/373 are capable of impacting CRC phenotypes in vitro, we next investigated the role of miR-372/373-expressing cells in vivo. Stable cells were subcutaneously implanted into the dorsal flank of nude mice to form xenograft tumors. Mice bearing miR-372/373-expressing cells formed tumors much faster than the control group in the initial days after injection (Fig. 2D–F), indicating that ectopic expression of miR-372/373 accelerates tumor formation of CRC in vivo. Western blot analysis showed that the protein levels of CSC markers CD44 and CD26 were upregulated in miR-372/373-overexpressing HCT116 cells in subcutaneously implanted tumors (Fig. 2G). These results indicate that overexpression of miR-372/373 enhanced tumor formation and increased the stem cell population of CRC in vivo.

3.3. miR-372/373 regulate stemness-related signaling pathways by targeting differentiation genes

Differentiation or stemness-related genes are generally involved in regulatory networks of key cell signaling pathways, and a single gene could be involved in different signaling pathways in different cellular contexts. To determine the major signaling pathways that are affected by miR-372/373 in CRC cells, we profiled cell signaling pathways after both transiently and stably overexpressing miR-372/373 in HCT116 cells. A Cignal 45-pathway Reporter Array luciferase system was used to determine the activity of various core transcription factors and generate a signaling activity map. A group
of pathways was significantly affected by miR-372 and miR-373 (Table S3). Particularly, we noted that stemness-related pathways, such as Hedgehog, c-Myc and Nanog signaling, were elevated and numerous pathways related to differentiation, such as NFκB, SP1, MAPK/Erk and vitamin D signaling, were markedly repressed when both transiently and stably overexpressing miR-372/373 in CRC cells (Fig. 3A).

miRNAs exert their function by repressing target genes. To further clarify the underlying mechanism responsible for the signaling pathway changes caused by miR-372/373, we predicted potential targets of miR-372/373 using TargetScan (Lewis et al., 2005) and starBase, version 2.0 (Li et al., 2014) and focused on the target genes that are involved in signaling pathway regulation (Fig. 3B and Table S4).

To validate the predicted targets that were suppressed by miR-372/373 in CRC cells, we constructed luciferase reporter plasmids containing the 3' UTR of each target. The 3' UTR activity of RELA, VDR, SETD7, SPOP, TRERF1, ZNF367 and MTUS1 was significantly repressed by miR-372/373 (Figs 3C and S3). Although the miR-372/373 target sites in the 3' UTRs linked to the luciferase reporter were mutagenized, all mutant sites lost their response to miR-372/373 (Figs 3C and S3A). The miR-372/373 target sites in the 3' UTRs of each target were repressed by miR-372/373 (Figs 3C and S3A). The 3' UTR activity of RELA, VDR, SETD7, SPOP, TRERF1, ZNF367 and MTUS1 was significantly repressed by miR-372/373 (Figs 3C and S3A). Although the miR-372/373 target sites in the 3' UTRs linked to the luciferase reporter were mutagenized, all mutant sites lost their response to miR-372/373 (Figs 3C and S3A), indicating the site-specificity of the repression. Quantitative RT-PCR analysis revealed that miR-372/373 downregulated the mRNA expression of these genes (Figs 3D and S3B), indicating a strong inhibitory effect. We then focused on and further investigated the protein levels of three new target genes, VDR, SETD7 and SPOP, all of which are involved in cell differentiation (Blomberg Jensen et al., 2012; Castano et al., 2016; Zhang et al., 2009; Zhou et al., 2017). Western blot analysis revealed that overexpression of miR-372/373 inhibited the protein levels of all the targets in both HCT116 and RKO cells, with the exception of SETD7 in an assay with miR-372 in RKO cells (Fig. 3E). Conversely, the protein levels of the three targets in Caco-2 miR-372/373-TuD cells were elevated (Fig. 3E). These results indicated that the expression of SPOP, VDR and SETD7 was repressed by miR-372/373 in CRC cells. It is worth noting that SPOP had a more significant change in response to the forced or alleviated expression of miR-372/373.

We also confirmed the pathway profiling data in stable-overexpressing cells by quantitative RT-PCR. Consistently, mRNA levels of Nanog are enhanced by miR-372/373 and mRNA of NFκB core factor RelA is suppressed by miR-372/373 (Figs 3F and S3C). To determine whether disruption of SPOP, VDR and SETD7 contributes to the pathway change, we performed a transient knockdown of these genes using siRNAs in HCT116 cells. All siRNAs significantly suppressed the protein levels of their target genes (Fig. S4A,B) and, to a certain extent, this resulted in increased expression of the Nanog gene and suppressed expression of the RelA gene (Fig. 3G, H). These results indicated that miR-372/373 target a series of genes to regulate signaling pathways in CRC cells.

### 3.4. Suppression of differentiation genes targeted by miR-372/373 contributes to the phenotype of CSC

To determine the impact of SPOP, VDR and SETD7 on differentiation and stemness in colon cancer cell, we first tested the overexpression effects of these genes and found that SPOP and SETD7 positively regulated the expression of goblet cell differentiation marker HATH1, whereas VDR promoted the expression of columnar epithelial cell marker lactase in HCT116 cells (Fig. S5A,B). Next, we analyzed the proportion of CD24+ and CD26+ CSC populations by FACS and the protein levels of VDR, SETD7 and SPOP by western blotting in three CRC cell lines. The CD24+ and CD26+ CSC populations are high in Caco-2 compared to RKO and HCT116 cells, whereas the expression of the target genes is low in Caco-2 compared to VDR, which is not that much different (Fig. S5C,D). We further performed a transient knockdown of VDR, SETD7 and SPOP using siRNAs in HCT116 cells and...
miR-372/373 induced cancer stem cell phenotypes

A. HCT116 pathway signaling

B. Signaling pathway related genes

C. Relative Luciferase Activity

D. Relative Expression

E. HCT116, RKO, Caco-2 TuD

F. miR-372/NC and miR-373/NC

G. Nanog

H. RelA
analyzed the CD24+ and CD26+ CSC populations. As shown in Fig. 4A, siRNA silencing of SPOP, VDR and SETD7 significantly increased CD24+ and/or CD26+ cells, suggesting that CSC populations are expanded by suppressing these three target genes.

To further confirm that miR-372/373 induced the CSC phenotype by targeting these genes in CRC, we knocked down each of the genes in Caco-2 miR-372/373-TuD cells. Although inhibition of miR-372 or miR-373 attenuated the population of CD24+ cells in Caco-2 cells, silencing all these targets by siRNAs at the same time relieved the suppression of the population of CD24+ cells in Caco-2 miR-372/373-TuD cells (Fig. 4B). These results revealed that miR-372/373 maintained the CSC phenotype, at least in part, by repressing SPOP, VDR and SETD7 in CRC.

In addition, we analyzed the expression of these genes in CRC patients from TCGA database. It is evident that the mRNA level of SPOP, VDR and SETD7 in CRC tissues is lower than in normal adjacent tissues (Fig. 5), indicating the tumor suppressive roles of these genes and the poor differentiation of CRC.

4. Discussion

It is assumed that 90% of CRC have an activation mutation of the Wnt/β-catenin pathway (Schneikert and Behrens, 2007). In the present study, we showed that miRNA-372/373 are upregulated in many CRC patient samples. This is consistent with the upregulated expression of Wnt/β-catenin signaling because miR-372/373 were transactivated by the pathway in CRC (Guo et al., 2016; Zhou et al., 2012). Furthermore, the expression level of miRNA-372/373 may reflect different degrees of activities that correspond to the status of stemness or poor differentiation of CRC cells, as well as higher cancer progression and recurrence rates in patients (Table S5). Thus, it may prove to be novel diagnostic marker and therapeutic target for the clinical staging of CRC.

Multiple genes are determined to be new targets of miR-372/373 in CRC cells in the present study. Interestingly, these genes are involved in diverse cellular biological processes with respect to differentiation. Among them, VDR is the nuclear receptor of 1,25-dihydroxyvitamin D3, which has been reported to induce differentiation of testicular germ cells and T cells (Blomberg Jensen et al., 2012; Zhou et al., 2017). SETD7 is a lysine methyltransferase that mediates the methylation of proteins and is induced during the differentiation of human ESCs (Castano et al., 2016). SPOP, an E3 ubiquitin ligase adaptor, mediates the ubiquitination and degradation of Gli2 and inhibits Hedgehog signaling, which affects cell differentiation (Zhang et al., 2009). In the present study, these three genes were confirmed to positively regulate differentiation markers in CRC cells (Fig. S5). We have also silenced other potential miR-372/373 targets, such as TRERF1, ZNF367 and MTUS1, by siRNA in HCT116 cells, and increased mRNA levels of the stem cell markers Nanog, Sox2, CD24, CD44 and CD26 were detected (Fig. S3D). TRERF1 and MTUS1 are reported to be involved in the differentiation in breast cancer cells (Gizard et al., 2006) and oral tongue squamous cell carcinoma (Ding et al., 2012), respectively. It has been reported that LAST2, DKK1 and TXNIP are targeted by miRNA-372/373 in different cancer cells (Voorhoeve et al., 2006; Yan et al., 2011; Zhou et al., 2012). Interestingly, these genes are required for the differentiation of adipocytes (An et al., 2013), neurons (Mukhopadhyay et al., 2001) and natural killer cells (Gasiorek et al., 2015; Lee et al., 2005), respectively. From our analytic data, inhibiting the expression of differentiation genes to maintain stemness is the major function of miRNA-372/373 in CRC and other cancers.

The cell signaling pathways regulated by miR-372/373 in CRC cells were systematically demonstrated in the present study. miRNA-372/373 significantly affected the activity of numerous pathways, indicating large-scale changes in gene regulation networks. These results demonstrated that miRNAs are strong epigenetic regulators and a powerful driving force to transform cell status. Remarkably, among all of these pathways, NFκB is the one that is most repressed by miR-372/373. It has been reported that the NFκB signal is able to trigger early differentiation of stem cells (Alvero et al., 2009; Luningschror et al., 2012; Nogueira et al., 2011; Pratt et al., 2009; Yang et al., 2010; Zhang et al., 2012). In both mouse and human ESCs, NFκB activity remains at a low level and increases remarkably during early differentiation (Luningschror et al., 2012; Yang et al., 2010; Zhang et al., 2012). Glioma initiation cells (GICs), comprising the only cell population with tumorigenic capacity in gliomas, are reported to have low NFκB activity that is upregulated during GIC differentiation (Nogueira et al., 2011). In addition, NFκB signaling is active in cancers and functions as a pro-inflammatory pathway to boost the proliferation of cancer cells and cancer progenitor cells (Karin, 2006). Thus, the NFκB signaling pathway is tightly involved in the initiation and maintenance of cancer cell differentiation and the antagonism towards stemness in both ESCs and CSCs. By contrast, miR-372/373 strongly suppress NFκB signaling to promote stemness, as clearly demonstrated in
Fig. 4. Knockdown of SPOP, VDR and SETD7 enhances the CRC stem cell phenotype. (A) Relative CD24+ and CD26+ cell populations in HCT116 cells transfected with the indicated siRNAs determined by FACS. (B) Relative CD24+ cell population measured by FACS in Caco-2 miR-372/373-TuD cells transfected with the indicated siRNAs. Error bars represent the SEM (n = 3). *P < 0.05 by Student’s t-test.
our pathway profiling analysis. The Wnt/β-catenin pathway plays an important role in stem cells and has been reported to suppress NFκB in CRC (Deng et al., 2002). Consistently, in the present study, we have confirmed that activation of Wnt/β-catenin signaling significantly inhibited the NFκB pathway in both HEK293T cells and HCT116 cells (Fig. S6). The results of the present study suggest that miR-372/373, as key effectors of Wnt/β-catenin signaling (Zhou et al., 2012), are undoubtedly major contributors to the crosstalk between the Wnt/β-catenin and NFκB pathways in CRC cells.

CSCs comprise a subpopulation of tumor cells with stem cell properties and are considered to have the capacity for tumor initiation (Creighton et al., 2009; Li et al., 2008; Song and Miele, 2007). CSCs could survive and expand in immune-deficient mice, differentiate to progeny cancer cells and fuel the growth of the tumor (Ricci-Vitiani et al., 2007). However, when tumors are formed, the CSCs are relatively quiescent compared to their differentiated progeny (Chen et al., 2012). The origin of CSCs remains to be determined, especially with respect to whether CSCs are derived from normal stem cells or cancer cells. Recently, it was reported that breast tumor-initiation cells originated in a region different from that of normal mammary stem cells, and it has been suggested that the apparently similar stem cell programs operating in tumor-initiation cells and normal stem cells of corresponding normal tissues are likely to differ significantly (Ye et al., 2015). It is currently assumed that CSC populations are dynamic and that cancer stemness is not a rigid feature but can be modulated and even induced by many factors, such as the tumor microenvironment and genetic or epigenetic mutations (Jordan et al., 2006; Vermeulen et al., 2010). The results of the present study showed that miR-372/373 impart a stem-like phenotype to CRC cells by regulating multiple factors involved in differentiation and stemness. The dynamic transition from cancer cells to CSCs within the CRC population is delineated, indicating that cancer cells can be induced to acquire self-renewal and chemotherapy resistance by stem cell-specific miRNA regulation. From the results obtained in the present study, we suggest that stem cell-specific RNAs such as miR-372/373 are strong endogenous inducers of CRC stem cells. Intriguingly, overexpression of miR-372/373 in the HCT116 cell line significantly increased other clusters of stem miRNAs, such as the miR-302 family, by which it may amplify the stem cell-like features in CRC cells (Xie et al., 2013). Our results are also consistent with studies of miR-302, which was reported to be upregulated in CSCs in head and neck squamous cell carcinoma and prostate cancer (Bourguignon et al., 2012; Guo et al., 2017). These results provide evidence for cancer cell plasticity via miRNA-driven epigenetic regulation, implying the origin of CSCs.

5. Conclusions

In summary, we report that excessive expression of the Wnt/β-catenin signaling downstream effector miR-372/373 enhances the stemness of CRC cells by targeting multiple genes/pathways involved in differentiation and stemness regulation. These findings highlight a crucial link between the stem-specific miRNAs and the acquisition of CSC properties in the CRC, and open the possibility for future therapeutic intervention.

Acknowledgements

We thank Qiao-Juan Huang, Yi-Ling Chen and Xiao-Hong Chen for their technical assistance. This work was supported by the National Natural Science Foundation of China (31230042, 31471223, 31671349, 31771459, 31770879); National Key R&D Program of
China (2017YFA0504400); and the project of Science and Technology of Guangzhou (201504010022).

**Author contributions**

L-QW and PY performed the experiments and analyzed the data. L-QW and L-HQ conceived the study and wrote the paper. BL, Z-RL, L-SZ, Y-HG and SL performed the experiments. L-LZ, J-HY, HX and HZ analyzed the data. L-QW and PY performed the experiments and analyzed the data. BL, Z-RL, L-SZ, Y-HG and SL performed the experiments. L-LQW and L-HQ revised the manuscript.

**References**

Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M, Visintin I et al. (2009) Molecular phenotyping of human ovarian cancer stem cells unavels the mechanisms for repair and chemoresistance. *Cell Cycle* 8, 158–166.

An Y, Kang Q, Zhao Y, Hu X and Li N (2013) Lats2 regulates adipocyte proliferation and differentiation via hippo signaling. *PLoS ONE* 8, e72042.

Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 116, 281–297.

Blomberg Jensen M, Jorgensen A, Nielsen JE, Steinmeyer A, Leffers H, Juul A and Rajpert-De Meyts E (2012) SETD7 regulates the differentiation of human embryonic stem cells. *PLoS One* 11, e0149502.

Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG and Parada LF (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. *Nature* 488, 522–526.

Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI et al. (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. *Proc Natl Acad Sci USA* 106, 13820–13825.

Deng J, Miller SA, Wang HY, Xia W, Wen Y, Zhou BP, Li Y, Lin SY and Hung MC (2002) beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. *Cancer Cell* 2, 323–334.

Ding X, Zhang N, Cai Y, Li S, Zheng C, Jin Y, Yu T, Wang A and Zhou X (2012) Down-regulation of tumor suppressor MTUS1/ATIP is associated with enhanced proliferation, poor differentiation and poor prognosis in oral tongue squamous cell carcinoma. *Mol Oncol* 6, 73–80.

Eyking A, Reis H, Frank M, Gerken G, Schmid KW and Cario E (2016) MiR-205 and MiR-373 are associated with aggressive human mucinous colorectal cancer. *PLoS ONE* 11, e0156871.

Garzon R, Fabbri M, Cimmino A, Calin GA and Croce CM (2006) MicroRNA expression and function in cancer. *Trends Mol Med* 12, 580–587.

Gasiorowicz JJ, Mikhail M, Garcia-Santos D, Hui ST, Ponka P and Blank V (2015) Thioredoxin-interacting protein regulates the differentiation of murine erythroid precursors. *Exp Hematol* 43, 393–403 e392.

Girard F, Robillard R, Gross B, Barbier O, Revillion F, Peyrat JP, Torpier G, Hum DW and Staels B (2006) TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone. *Mol Cell Biol* 26, 7632–7644.

Guo Y, Cui J, Ji Z, Cheng C, Zhang K, Zhang C, Chu M, Zhao Q, Yu Z, Zhang Y et al. (2017) miR-302/367/LATS2/YAP pathway is essential for prostate tumor-propagating cells and promotes the development of castration resistance. *Oncogene* 36, 6336–6347.

Guo YH, Wang LQ, Li B, Xu H, Yang JH, Zheng LS, Yu P, Zhou AD, Zhang Y, Xie SJ et al. (2016) Wnt/beta-catenin pathway transactivates microRNA-150 that promotes EMT of colorectal cancer cells by suppressing CREB signaling. *Oncotarget* 7, 42513–42526.

Haraguchi T, Ozaki Y and Iba H (2009) Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. *Nucleic Acids Res* 37, e43.

Huang HL, Weng HY, Wang LQ, Yu CH, Huang QJ, Zhao PP, Wen JZ, Zhou H and Qu LH (2012) Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis. *Mol Cancer Ther* 11, 1155–1165.

Ivey KN and Srivastava D (2010) MicroRNAs as regulators of differentiation and cell fate decisions. *Cell Stem Cell* 7, 36–41.

Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH et al. (2009) Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. *Hepatology* 50, 472–480.
Ji J, Yamashita T and Wang XW (2011) Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. *Cell Biosci* 1, 4.

Jia Y, Liu H, Zhuang Q, Xu S, Yang Z, Li J, Lou J and Zhang W (2012) Tumorigenicity of cancer stem-like cells derived from hepatocarcinoma is regulated by microRNA-145. *Oncol Rep* 27, 1865–1872.

Jordan CT, Guzman ML and Noble M (2006) Cancer stem cells. *N Engl J Med* 355, 1253–1261.

Judson RL, Greve TS, Parchem RJ and Blelow R (2013) MicroRNA-based discovery of barriers to dedifferentiation of fibroblasts to pluripotent stem cells. *Nat Struct Mol Biol* 20, 1227–1235.

Karin M (2006) Nuclear factor-kappaB in cancer development and progression. *Nature* 441, 431–436.

King JB, von Furstenberg RJ, Smith BJ, McNaughton KK, Galanko JA and Henning SJ (2012) CD24 can be used to isolate Lgr5+ putative colonic epithelial stem cells in mice. *Am J Physiol Gastrointest Liver Physiol* 303, G443–G452.

Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M et al. (2007) A mammalian microRNA expression atlas based on small RNA library sequencing. *Cell* 129, 1401–1414.

Lee KN, Kang HS, Jeon JH, Kim EM, Yoon SR, Song H, Lyu CY, Piao ZH, Kim SU, Han YH et al. (2005) VDUP1 is required for the development of natural killer cells. *Immunity* 22, 195–208.

Lewis BP, Burge CB and Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* 120, 15–20.

Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Hammond GC et al. (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. *J Natl Cancer Inst* 100, 672–679.

Li J-H, Liu S, Zhou H, Qu L-H and Yang J-H (2014) starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. *Nucleic Acids Res* 42, D92–D97.

Lin SL, Chang DC, Lin CH, Ying SY, Leu D and Wu DT (2011) Regulation of somatic cell reprogramming through inducible mir-302 expression. *Nucleic Acids Res* 39, 1054–1065.

Loayza-Puch F, Yoshida Y, Matsuzaki T, Takahashi C, Kitayama H and Noda M (2010) Hypoxia and RAS-signaling pathways converge on, and cooperatively downregulate, the RECK tumor-suppressor protein through microRNAs. *Oncogene* 29, 2638–2648.

Luningschorr P, Stocker B, Kaltenschmidt B and Kaltenschmidt C (2012) miR-290 cluster modulates pluripotency by repressing canonical NF-kappaB signaling. *Stem Cells* 30, 655–664.

Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, Ng I, Man K, Wong N, To KF et al. (2010) miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. *Cell Stem Cell* 7, 694–707.

Mukhopadhyay M, Shtrom S, Rodriguez-Esteban C, Chen L, Tsukui T, Gomer L, Dorward DW, Glinka A, Grinberg A, Huang SP et al. (2001) Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. *Dev Cell* 1, 423–434.

Nogueira L, Ruiz-Ontanon P, Vazquez-Barquero A, Lafarga M, Berciano MT, Aldaz B, Grande L, Casafont I, Segura V, Robles EF et al. (2011) Blockade of the NFkappaB pathway drives differentiating glioblastoma-initiating cells into senescence both in vitro and in vivo. *Oncogene* 30, 3537–3548.

O’Brien CA, Pollett A, Gallinger S and Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature* 445, 106–110.

Pang R, Law WL, Chu ACY, Poon JT, Lam CSC, Chow AKM, Ng L, Cheung LWH, Lan XR, Lan HY et al. (2010) A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. *Cell Stem Cell* 6, 603–615.

Pfaff N, Fiedler J, Holzmann A, Schambach A, Moritz T, Cantz T and Thum T (2011) miRNA screening reveals a new miRNA family stimulating iPS cell generation via regulation of Meox2. *EMBO Rep* 12, 1153–1159.

Pratt MA, Tibbo E, Robertson SJ, Jansson D, Hurst K, Perez-Iratxeta C, Lau R and Niu MY (2009) The canonical NF-kappaB pathway is required for formation of luminal mammary neoplasias and is activated in the mammary progenitor population. *Oncogene* 28, 2710–2722.

Ren D, Wang M, Guo W, Zhao X, Tu X, Huang S, Zou X and Peng X (2013) Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR145. *Int J Oncol* 42, 1473–1481.

Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C and De Maria R (2007) Identification and expansion of human colon-cancer-initiating cells. *Nature* 445, 111–115.

Schneekurt J and Behrens J (2007) The canonical Wnt signaling pathway and its APC partner in colon cancer development. *Gut* 56, 417–425.

Song LL and Miele L (2007) Cancer stem cells—an old idea that’s new again: implications for the diagnosis and treatment of breast cancer. *Expert Opin Biol Ther* 7, 431–438.

Subramanyam D, Lamouille S, Judson RL, Liu JY, Bucay N, Derynck R and Blelow R (2011) Multiple targets
of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. *Nat Biotechnol* **29**, 443–448.

Suh MR, Lee Y, Kim JY, Kim SK, Moon SH, Lee JY, Cha KY, Chung HM, Yoon HS, Moon SY *et al.* (2004) Human embryonic stem cells express a unique set of microRNAs. *Dev Biol* **270**, 488–498.

Tanaka T, Araï M, Wu S, Kanda T, Miyauchi H, Imazeki F, Matsubara H and Yokosuka O (2011) Epigenetic silencing of microRNA-373 plays an important role in regulating cell proliferation in colon cancer. *Oncol Rep* **26**, 1329–1335.

Vermeulen L, De Sousa E, Melo F, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C *et al.* (2010) Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. *Nat Cell Biol* **12**, 468–476.

Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M *et al.* (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci USA* **103**, 2257–2261.

Voorhoeve PM, le Sage C, Schrier M, Gillis AJM, Stoop H, Nagel R, Liu Y-P, van Duijse J, Drost J, Griekspoor A *et al.* (2005) A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. *Cell* **124**, 1169–1181.

Wang Y, Yu Y, Tsuaya A, Ren X, Wu X, Stubblefield K, Rankin-Gee EK and Wang SE (2011) Transforming growth factor-beta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. *Oncogene* **30**, 1470–1480.

Wienholds E, Kloosterman WP, Miska E, Alvarez-Saavedra E, Berezikov E, de Bruijn E, Horvitz HR, Kauppinen S and Plasterk RHA (2005) MicroRNA expression in zebrafish embryonic development. *Science* **309**, 310–311.

Xie S, Zhang Y, Qu L and Xu H (2013) A Helm model for microRNA regulation in cell fate decision and conversion. *Sci China Life Sci* **56**, 897–906.

Xu H, He J-H, Xiao Z-D, Zhang Q-Q, Chen Y-Q, Zhou H and Qu L-H (2010) Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. *Hepatology* **52**, 1431–1442.

Xu N, Papagiannakopoulos T, Pan G, Thomson JA and Kosik KS (2009) MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. *Cell* **137**, 647–658.

Yamashita S, Yamamoto H, Mimori K, Nishida N, Takahashi H, Haraguchi N, Tanaka F, Shibata K, Sekimoto M, Ishii H *et al.* (2012) MicroRNA-372 is associated with poor prognosis in colorectal cancer. *Oncology* **82**, 205–212.

Yan GR, Xu SH, Tan ZL, Liu L and He QY (2011) Global identification of miR-373-regulated genes in breast cancer by quantitative proteomics. *Proteomics* **11**, 912–920.

Yang C, Atkinson SP, Vilella F, Lloret M, Armstrong L, Mann DA and Lako M (2010) Opposing putative roles for canonical and noncanonical NFkappaB signaling on the survival, proliferation, and differentiation potential of human embryonic stem cells. *Stem Cells* **28**, 1970–1980.

Ye X, Tam WL, Shibue T, Kaygusuz Y, Reinhardt F, Ng Eaton E and Weinberg RA (2015) Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. *Nature* **525**, 256–260.

Yeung TM, Gandhi SC, Wilding JL, Muschel R and Bodmer WF (2010) Cancer stem cells from colorectal cancer-derived cell lines. *Proc Natl Acad Sci USA* **107**, 3722–3727.

Zhang Y, Liu J, Yao S, Li F, Xin L, Lai M, Bracchi-Ricard V, Xu H, Yen W, Meng W *et al.* (2012) Nuclear factor kappa B signaling initiates early differentiation of neural stem cells. *Stem Cells* **30**, 510–524.

Zhang Q, Shi Q, Chen Y, Yue T, Li S, Wang B and Jiang J (2009) Multiple Ser/Thr-rib-rich degrons mediate the degradation of Ci/Gli by the Cul3-HIB/SPOP E3 ubiquitin ligase. *Proc Natl Acad Sci USA* **106**, 21191–21196.

Zhou AD, Diao LT, Xu H, Xiao ZD, Li JH, Zhou H and Qu LH (2012) beta-Catenin/LEF1 transactivates the microRNA-371-373 cluster that modulates the Wnt/beta-catenin-signaling pathway. *Oncogene* **31**, 2968–2978.

Zhou Q, Qin S, Zhang J, Zhou L, Pen Z and Xing T (2017) 1,25(OH)2D3 induces regulatory T cell differentiation by influencing the VDR/PLC-gamma1/TGF-beta1/pathway. *Mol Immunol* **91**, 156–164.

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Fig. S1.** Statistical correlation between miR-372/373 and stem cell markers and efficiency of lentivirus generated stable miR-372/373 ectopic or repressed cell lines.

**Fig. S2.** miR-372/373 induced stem cell-like phenotype of RKO cells and HCT116 cells and promoted migration and invasion potency in RKO cells.

**Fig. S3.** miR-372/373 increased the expression of Nanog, suppressed the expression of RelA and directly targeted a series of targets to induce cancer stem cell phenotype.

**Fig. S4.** Knockdown efficiency of indicated siRNAs in HCT116 cells.

Molecular Oncology **12** (2018) 1949–1964 © 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
miR-372/373 induced cancer stem cell phenotypes

L.-Q. Wang et al.

**Fig. S5.** The effect of enforced expression of VDR, SPOP and SETD7 on colon epithelial differentiation markers and the levels of VDR, SPOP, SETD7, CD24+ and CD26+ cells in colon cancer cell lines.

**Fig. S6.** RelA is suppressed by miR-372/373 and Wnt signaling.

**Table S1.** Primers used for reverse transcription and real-time PCR.

**Table S2.** Primers used for vector construction.

**Table S3.** Relative activity of pathways suppressed and enhanced in miR-372/373 transiently and stably over-expressing cells determined by luciferase reporter assays.

**Table S4.** Predicted target genes involved in signaling pathway regulation.

**Table S5.** Clinico-pathological variables and the expression of miR-372 in colon cancer patients.